Literature DB >> 20941600

Polyclonal expansion of human CD4(+)CD25(+) regulatory T cells.

Petra Hoffmann1, Ruediger Eder, Matthias Edinger.   

Abstract

Based on results from experimental animal models, the adoptive transfer of CD4(+)CD25(+)FOXP3(+) regulatory T cells (Treg) is expected to be efficacious in treating autoimmune and inflammatory diseases, as well as in preventing alloresponses after solid organ or stem-cell transplantation. For potential clinical applications, large numbers of Treg cells in maximum purity will be required to avoid the risk of disease exacerbation by contaminating effector T cells. We have recently described methods for the efficient in vitro expansion of human Treg cells and identified CD4(+)CD25(high)CD45RA(+) T cells as the ideal starting population for the generation of homogeneous and stable Treg cell products. Here, we provide detailed instructions for their identification, isolation, expansion, and functional characterization.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20941600     DOI: 10.1007/978-1-60761-869-0_2

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  7 in total

1.  Overexpression of CD45RA isoforms in carriers of the C77G mutation leads to hyporeactivity of CD4+CD25highFoxp3+ regulatory T cells.

Authors:  C Pokoyski; T Lienen; S Rother; E Schock; A Plege-Fleck; R Geffers; R Schwinzer
Journal:  Genes Immun       Date:  2015-09-10       Impact factor: 2.676

2.  Ex vivo-expanded but not in vitro-induced human regulatory T cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T cell-specific demethylated region.

Authors:  Maura Rossetti; Roberto Spreafico; Suzan Saidin; Camillus Chua; Maryam Moshref; Jing Yao Leong; York Kiat Tan; Julian Thumboo; Jorg van Loosdregt; Salvatore Albani
Journal:  J Immunol       Date:  2014-12-01       Impact factor: 5.422

3.  A Novel GMP Protocol to Produce High-Quality Treg Cells From the Pediatric Thymic Tissue to Be Employed as Cellular Therapy.

Authors:  Esther Bernaldo-de-Quirós; Beatriz Cózar; Rocío López-Esteban; Maribel Clemente; Juan Miguel Gil-Jaurena; Carlos Pardo; Ana Pita; Ramón Pérez-Caballero; Manuela Camino; Nuria Gil; María Eugenia Fernández-Santos; Susana Suarez; Marjorie Pion; Marta Martínez-Bonet; Rafael Correa-Rocha
Journal:  Front Immunol       Date:  2022-05-16       Impact factor: 8.786

Review 4.  A New Generation of Cell Therapies Employing Regulatory T Cells (Treg) to Induce Immune Tolerance in Pediatric Transplantation.

Authors:  Esther Bernaldo-de-Quirós; Marjorie Pion; Marta Martínez-Bonet; Rafael Correa-Rocha
Journal:  Front Pediatr       Date:  2022-05-11       Impact factor: 3.569

5.  Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders.

Authors:  Manuel Wiesinger; Diane Stoica; Susanne Roessner; Carmen Lorenz; Anika Fischer; Raja Atreya; Clemens F Neufert; Imke Atreya; Alexander Scheffold; Beatrice Schuler-Thurner; Markus F Neurath; Gerold Schuler; Caroline J Voskens
Journal:  Front Immunol       Date:  2017-10-26       Impact factor: 7.561

6.  Automated Clinical Grade Expansion of Regulatory T Cells in a Fully Closed System.

Authors:  José Manuel Marín Morales; Nadine Münch; Katja Peter; Daniel Freund; Uta Oelschlägel; Kristina Hölig; Thea Böhm; Anne-Christine Flach; Jörg Keßler; Ezio Bonifacio; Martin Bornhäuser; Anke Fuchs
Journal:  Front Immunol       Date:  2019-02-01       Impact factor: 7.561

Review 7.  Therapeutic application of T regulatory cells in composite tissue allotransplantation.

Authors:  Jeong-Hee Yang; Seok-Chan Eun
Journal:  J Transl Med       Date:  2017-10-26       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.